Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro

Journal of Pathology

Volumn 230, Issue 4, 2013, Pages 441-452

  Wang, Jia ^a   Zhao, Jingmin ^b   Chu, Eagle S H ^a   Mok, Myth T S ^a   Go, Minnie Y Y ^a   Man, Kwan ^c   Heuchel, Rainer ^d   Lan, Hui Yao ^a   Chang, Zhijie ^e   Sung, Joseph J Y ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BEIJING 302 HOSPITAL   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Tsinghua University   (China)

Author keywords

animal model; hepatocellular carcinoma; Smad7; tumour suppressor

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN D1; DIETHYLNITROSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMAL MODEL; HEPATOCELLULAR CARCINOMA; SMAD7; TUMOUR SUPPRESSOR;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL PROLIFERATION; DIETHYLNITROSAMINE; G1 PHASE; GENES, REPORTER; GENETIC PREDISPOSITION TO DISEASE; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PHENOTYPE; PRIMARY CELL CULTURE; S PHASE; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84880112620     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4206     Document Type: Article

References (32)

1. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Gressner OA, Rizk MS, Kovalenko E, et al., Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23: 1024-1035.
4. Yan X, Chen YG,. Smad7: not only a regulator, but also a cross-talk mediator of TGFβ signalling. Biochem J 2011; 434: 1-10.
5. Dooley S, Hamzavi J, Ciuclan L, et al., Hepatocyte-specific Smad7 expression attenuates TGFβ-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-659.
6. Hamzavi J, Ehnert S, Godoy P, et al., Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med 2008; 12: 2130-2144.
7. Javelaud D, Delmas V, Moller M, et al., Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 2005; 24: 7624-7629.
8. Azuma H, Ehata S, Miyazaki H, et al., Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst 2005; 97: 1734-1746.
9. Rizzo A, Waldner MJ, Stolfi C, et al., Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res 2011; 71: 7423-7432.
10. Leivonen SK, Ala-Aho R, Koli K, et al., Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 2006; 25: 2588-2600.
11. Javelaud D, Mohammad KS, McKenna CR, et al., Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007; 67: 2317-2324.
12. Halder SK, Beauchamp RD, Datta PK,. Smad7 induces tumorigenicity by blocking TGFβ-induced growth inhibition and apoptosis. Exp Cell Res 2005; 307: 231-246.
13. Liu X, Lee J, Cooley M, et al., Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 2003; 63: 7760-7768.
14. Edlund S, Bu S, Schuster N, et al., Transforming growth factor-β1 (TGFβ1)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGFβ-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 2003; 14: 529-544.
15. Kleeff J, Ishiwata T, Maruyama H, et al., The TGFβ signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-5372.
16. Yu J, Shen B, Chu ES, et al., Inhibitory role of peroxisome proliferator-activated receptor-γ in hepatocarcinogenesis in mice and in vitro. Hepatology 2010; 51: 2008-2019.
17. Li R, Rosendahl A, Brodin G, et al., Deletion of exon I of SMAD7 in mice results in altered B cell responses. J Immunol 2006; 176: 6777-6784.
18. Cuzzocrea S, Chatterjee PK, Mazzon E, et al., Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 2002; 135: 496-510.
19. Zhang JJ, Xu ZM, Zhang CM, et al., Pyrrolidine dithiocarbamate inhibits nuclear factor-κB pathway activation, and regulates adhesion, migration, invasion and apoptosis of endometriotic stromal cells. Mol Hum Reprod 2011; 17: 175-181.
20. Lee JS, Chu IS, Mikaelyan A, et al., Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311.
21. Zhu L, Wang L, Wang X, et al., Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS One 2011; 6: e17415.
22. 1-S progression in rat hepatocytes. J Biol Chem 2003; 278: 31691-31700.
23. 1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 2009; 69: 6565-6572.
24. 1-S phase transition in human keratinocytes. Cancer Res 2005; 65: 9287-9293.
25. Che Y, Ye F, Xu R, et al., Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012; 180: 1798-1807.
26. 1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 2003; 65: 1777-1785.
27. Dohi T, Beltrami E, Wall NR, et al., Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127.
28. Tamm I, Wang Y, Sausville E, et al., IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
29. Luedde T, Schwabe RF,. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118.
30. Wang W, Huang XR, Li AG, et al., Signaling mechanism of TGFβ1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005; 16: 1371-1383.
31. Wertz IE, Dixit VM,. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harb Perspect Biol 2010; 2: a003350.
32. Kang Y, He W, Tulley S, et al., Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005; 102: 13909-13914.